Ken Kohn PhD - EVP of Licensing Operations
KERMODE BIOTECHNOLOGIES

Dr. Kohn has over 30 years of experience in intellectual property protection and litigation in the health sciences sector. He is currently the Principal Executive at Kohn & Associates in Michigan.

​

Dr. Kohn's doctoral background in Immunology and Pharmacology, combined with his legal expertise, has allowed him to be involved in high-profile projects. These include extensive coverage in the CRISPR gene editing space, early breast cancer gene and introns for Francis Collins, the dendritic chemistry portfolio for Dr. George Newkome – NIH, blood chemistry analysis for Difco Sciences (now Becton Dickinson), and the intellectual property portfolio for Pfizer’s launch of Lyrica, among others.

​

Dr. Kohn has published several scientific papers on porphyrin and prostaglandin chemistry in top journals and has presented at numerous conferences focused on the most predominant intellectual property issues in the health sciences sector. Additionally, he is a member or affiliate of the American Bar Association, Association of University Technology Managers, Inc. (AUTM), Economic Club of Detroit, Michigan Biosciences Industry Association, Michigan Patent Law Association, and the State Bar of Michigan.